iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Dr Reddy's step-down subsidiary collaborates with Olema Pharmaceuticals

10 Jun 2022 , 10:26 AM

Dr Reddy’s Laboratories Limited announced that its wholly-owned subsidiary Aurigene Discovery Technologies Limited (Aurigene) has entered into an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target, with Olema Pharmaceuticals Limited.

As per the terms of the agreement, Olema will make an upfront licensing payment of US $8 million in exchange for rights to a pre-existing Aurigene program. Aurigene seeks to receive up to US $60 million in potential clinical development and regulatory milestones. Further, it is also eligible to receive up to US $370 million in potential commercial milestones, and royalties ranging from the mid-single digits to the low double digits on the basis of annual net sales.

During the research term, Olema will provide funding to Aurigene for the smooth functioning of ongoing discovery efforts. It has sufficient cash flows to fund Aurigene’s planned research and development operations into 2024.

“Company’s agreement with Olema further validates Aurigene’s extensive expertise in the discovery and preclinical development of effective cancer therapeutics,” commented Murali Ramachandra, Ph.D., Chief Executive Officer of Aurigene.

Olema and Aurigene will be jointly responsible to direct further preclinical work. If successful, Olema will act as a leader in clinical development as well as regulatory and commercial activities.

Dr Reddys Laboratories is currently trading at Rs4,336.35 up by Rs10.25 or 0.24% from its previous closing of Rs4,326.10 on the BSE. The scrip opened at Rs4,326 and has touched intraday high and low of Rs4,344 and Rs4,283.80 respectively.

Related Tags

  • Dr Reddy’s Laboratories agreement
  • Dr Reddy’s Laboratories Share
  • Dr Reddy’s Laboratories Stock
  • Dr Reddy’s Laboratories Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.